KN046 + gemcitabine + nab-paclitaxel

KN046 + gemcitabine + nab-paclitaxel is a combination regimen used in oncology clinical trials, particularly investigated as a first-line or subsequent treatment for solid tumors, including pancreatic cancer and non-small cell lung cancer. **KN046** is a recombinant humanized bispecific antibody targeting PD-L1 and CTLA-4 checkpoints—it blocks both PD-L1/PD-1 and CTLA-4/CD80 or CD86 interactions, leading to dual immune checkpoint blockade. This boosts T cell activation and reduces regulatory T cell-induced immune suppression in the tumor microenvironment, aiming to enhance antitumor immunity while maintaining a favorable safety profile compared to dual ICI therapy. **Gemcitabine** is a nucleoside analog (antimetabolite) inhibiting DNA synthesis, leading to apoptosis in rapidly dividing cells. **Nab-paclitaxel** (albumin-bound paclitaxel) is a microtubule stabilizing agent; the albumin-bound formulation enables enhanced delivery to tumor cells and reduces the risk of solvent-related toxicities. The combination is under investigation for its potential to synergistically improve outcomes in pancreatic cancer and possibly other advanced solid tumors by uniting cytotoxic chemotherapy with broad immune checkpoint blockade[1][3][4][5][7].

Other names

nab-paclitaxelalbumin-bound paclitaxel